Endoglin and CD-34 immunoreactivity in the assessment of microvessel density in normal pituitary and adenoma subtypes

Neoplasma

Volumn 57, Issue 6, 2010, Pages 591-593

  Rotondo, F ^a   Sharma, S ^a   Scheithauer, B W ^b   Horvath, E ^a   Syro, L V ^c   Cusimano, M ^d   Nassiri, F ^d   Yousef, G M ^a   Kovacs, K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAYO CLINIC   (United States)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angiogenesis; CD34; Endoglin; Immunohistochemistry; Microvascular density; Pituitary

Indexed keywords

CD34 ANTIGEN; DOPAMINE RECEPTOR STIMULATING AGENT; ENDOGLIN; SOMATOSTATIN DERIVATIVE; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ACTH SECRETING ADENOMA; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MICROVASCULATURE; MICROVESSEL DENSITY; PROLACTINOMA; PROTEIN EXPRESSION; THYROTROPIN SECRETING ADENOMA; ADENOMA; CHEMISTRY; HYPOPHYSIS; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; VASCULARIZATION;

ADENOMA; ANTIGENS, CD; ANTIGENS, CD34; HUMANS; IMMUNOHISTOCHEMISTRY; MICROVESSELS; PITUITARY GLAND; PITUITARY NEOPLASMS; RECEPTORS, CELL SURFACE;

EID: 84863412761     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2010_06_590     Document Type: Article

References (26)

1. FOLKMAN J. ANGIOGENESIS. IN: JAFFE EA, ed. Biology of endothelial cells. The Hague, The Netherlands: Nijhoff, 1984: 412-428.
2. FOLKMAN J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6. doi:10.1093/jnci/82.1.4
3. JUGENBURG M, KOVACS K, STEFANEANU L, SCHEITHAUER BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol 1995; 6: 115-124. doi:10.1007/BF02739874
4. JUGENBURG M, KOVACS K, JUGENBURG I, SCHEITHAUER BW. Angiogenesis in endocrine neoplasms. Endocr Pathol 1997; 8: 259-272. doi:10.1007/BF02739928
5. VIDAL S, SCHEITHAUER BW, KOVACS K. Vascularity in nontumorous human pituitaries and incidental microadenomas: a morphometric study. Endocr Pathol 2000; 11: 215-227. doi:10.1385/EP:11:3:215
6. TURNER HE, NAGY Z, GATTER KC, ESIRI MM, Wass JA. Angiogenesis in pituitary adenomas and normal pituitary gland. J Clin Endocrinol Metab 2000; 85: 1159-1162. doi:10.1210/jc.85.3.1159
7. PAWLIKOWSKI M, PISAREK H, JARANOWSKA M. Immunocytochemical investigations on the vascularisation of pituitary adenomas. Endocr Pathol 1997; 8: 189-193. doi:10.1007/BF02738785
8. VIDAL S, KOVACS K, HORVATH E, SCHEITHAUER BW, KUROKI T, et al. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 2001; 438: 595-602. doi:10.1007/s004280000373
9. BEHREM S, ZARKOVIC K, ESKINJA N, JONJIC N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat Med J 2005; 46: 417-422.
10. FONSATTI E, SIGALOTTI L, ARSLAN P, ALTOMONTE M, MAIO M. Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003; 3: 427-432. doi:10.2174/1568009033481741
11. DUFF SE, LI C, GARLAND JM, KUMAR S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17: 984-992. doi:10.1096/fj.02-0634rev
12. FONSATTI E, DEL VECCHIO L, ALTOMONTE M, SIGALOTTI E, NIKOTRA MR, et al. Endoglin: an accessory component of the TGF-β binding receptor-complex with diagnostic, prognostic and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001; 188: 1-7. doi:10.1002/jcp.1095
13. FONSATTI E, MAIO M. HIGHLIGHTS ON ENDOGLIN (CD105): from basic findings toward clinical applications in human cancer. J Transl Med 2004; 2: 18. doi:10.1186/1479-5876-2-18
14. ROTONDO F, KOVACS K, HORVATH E, BELL CD, LLOYD RV, SCHEITHAUER BW. Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms. Acta Neuropathol 2006; 111: 272-277. doi:10.1007/s00401-006-0031-6
15. KOVACS K, HORVATH E, VIDAL S. Classification of pituitary adenomas. J Neuro-Oncol 2001; 54: 121-127. doi:10.1023/A:1012945129981
16. KOVACS K, SCHEITHAUER BW, HORVATH E, LLOYD RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996; 78: 502-510. doi:10.1002/(SICI)1097-0142(19960801)78:3<502::AIDCNCR18> 3.0.CO;2-2
17. LASTRES P, LETAMENDIA A, ZHANG H, RIUS C, ALMENDRO N, et al. Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996; 133: 1109-1121. doi:10.1083/jcb.133.5.1109
18. LETAMENDIA A, LASTRES P, BOTELLA LM, RAAB U, LANGA C, et al. Role of endoglin in cellular responses to transforming growth factor-β. A comparative study with betaglycan. J biol Chem 1998; 273: 33011-33019. doi:10.1074/jbc.273.49.33011
19. BARBARA NP, WRANA JL, LETARTE M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999; 274: 584-594. doi:10.1074/jbc.274.2.584
20. CHEIFETZ S, BELLON T, CALES C, VERA S, BERNABEU C, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-19030.
21. LEBRIN F, DECKERS M, BERTOLINO P, TEN DIJK P. TGF-β receptor function in the endothelium. Cardiovasc Res 2005; 65: 599-608. doi:10.1016/j.cardiores.2004.10.036
22. RIUS C, SMITH JD, ALMENDRO N, LANGA C, BOTELLA LM, et al. Cloning of the promoter region of human endoglin, the target Gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998; 92: 4677-90.
23. PIZARRO CB, OLIVEIRA MC, PEREIRA-LIMA JF, LEAES CG, KRAMER CK, et al. Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathol 2009; 29: 40-44. doi:10.1111/j.1440-1789.2008.00937.x
24. DALLAS NA, SAMUEL S, XIA L, FAN F, GRAY MJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008; 14: 1931-1937. doi:10.1158/1078-0432.CCR-07-4478
25. KOVACS K, STEFANEANU L, HORVATH E, LLOYD RV, LANCRANJAN T, et al. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and In situ hybridization. Virchows Arch 1991; 418: 439-446. doi:10.1007/BF01605931
26. EZZAT S, HORVATH E, HARRIS AG. Morphological effects of octreotide on growth hormone producing pituitary adenomas. J Clin Endocrinol Metab 1994; 74: 113-118. doi:10.1210/jc.79.1.113